Equities Analysts Offer Predictions for DWTX FY2025 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Investment analysts at Zacks Small Cap reduced their FY2025 EPS estimates for shares of Dogwood Therapeutics in a note issued to investors on Monday, November 10th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($15.31) per share for the year, down from their prior estimate of ($8.71). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share.

Several other equities analysts have also recently weighed in on DWTX. HC Wainwright lifted their price target on Dogwood Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dogwood Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Down 2.9%

NASDAQ:DWTX traded down $0.17 during trading hours on Thursday, hitting $5.66. 4,768 shares of the company traded hands, compared to its average volume of 1,473,339. The company has a market cap of $12.96 million, a PE ratio of -0.23 and a beta of 1.86. The firm’s 50-day simple moving average is $5.73 and its 200-day simple moving average is $5.22. Dogwood Therapeutics has a one year low of $1.62 and a one year high of $29.28.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($8.20) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($6.97).

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.